The Hematology-Lymphoma Biobank plans to collect blood, saliva, serum and cell-free DNA from every lymphoma patient, in addition to the residual material available from the Pathology department (tumor tissue), the Hematology department and the Laboratory of Hematology (bone marrow, peripheral blood and tumor tissue). In recent years, much progress has been made in the knowledge surrounding the processes involved in the development and progression of lymph node cancer and the response to therapy. The aim and ambition of HEMLYM is to improve the diagnosis and treatment of patients with lymphoma.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items

First implications of the Radboud Biobank new business model
15 July 2025It was communicated in an earlier news item that the Radboudumc Board of Directors decided to change the Radboud Biobank business model.
read more
Relocation of Radboud Biobank samples to Central Freezing Facility
15 July 2025The Radboud Biobank has now transferred almost all stored samples to the central freezing facility.
read more
Standardized Radboud Biobank procedures for sample handling in Elabgids
15 July 2025The Radboud Biobank is currently preparing to include all standardized Radboud Biobank procedures for sample handling in the eLabgids.
read more
Temporary new location Radboud Biobank Office
15 July 2025The Radboud Biobank office has moved to a temporary new location: route 832 - M325.04.255 (building F).
read more
Europe Biobank Week 2025
15 July 2025The Europe Biobank Week 2025 was a great success for the Dutch biobank community with a strong presence of Dutch biobanking and biomedical research.
read more
National Biobanks & Collections Dag 2025
6 May 2025The second edition of the National Biobanks & Collections Day took place on March 27, 2025, in Nijmegen and attracted 150 participants from all over the Netherlands.
read more